Extended follow-up from the DREAMM-2 trial

The potential of belantamab mafodotin (belamaf) in the relapsed or refractory (R/R) multiple myeloma (MM) setting was highlighted in 2019, when the pivotal DREAMM-2 study met its primary endpoint.

Read the full article here

Related Articles